Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...
Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback